Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference

THOUSAND OAKS, Calif., Sept. 14 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will participate in the Bank of America Merrill Lynch Global Healthcare Conference on Thursday, Sept. 16, 2010, in London, beginning at 9:50 a.m. Greenwich Mean Time.  Amgen executives Rolf Hoffmann, senior vice president, International Commercial Operations; Willard Dere, M.D., senior vice president, International Chief Medical Officer; and Arvind Sood, vice president, Investor Relations, will participate in the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's website, www.amgen.com, under Investors.

Information regarding presentation time, webcast availability, and webcast links are available on Amgen's Investor Relations Events Calendar.  

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics.  A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient.  Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses.  With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.  To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

CONTACT: Amgen, Thousand Oaks

David Polk, 805-447-4613 (media)

John Shutter, 805-447-1060 (investors)



(Logo:  http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO)

SOURCE Amgen

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.